Dogwood Therapeutics (NASDAQ:DWTX) Releases Quarterly Earnings Results, Misses Expectations By $4.80 EPS

Dogwood Therapeutics (NASDAQ:DWTX) released its earnings results on Monday. The company reported ($6.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($4.80), Zacks reports.

Dogwood Therapeutics Stock Performance

Shares of NASDAQ:DWTX opened at $5.01 on Tuesday. Dogwood Therapeutics has a one year low of $1.62 and a one year high of $29.28. The company has a market cap of $6.67 million, a P/E ratio of -0.76 and a beta of 2.07. The company has a 50 day moving average of $7.73.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.